Silence Therapeutics Inc. (SLN): Price Target Chart

Corporate company logo of Silence Therapeutics PLC (SLN)

The price history of Silence Therapeutics (SLN) shares on the GURU.Markets platform, where the current indicator is 20.05, is based on achievements in siRNA therapy for the heart. Trial results and payments from pharma behemoths are driving growth. The team retains leading RNA experts through a system of grants and bonuses. Treatment efficacy determines business success, as macroeconomics only influences general investment sentiment.

SLN (Silence Therapeutics PLC) Analyst Consensus Forecast history from 06/21/2023 to 11/11/2026
Manufactured products of Silence Therapeutics Inc.

This indicator represents the weighted average fair value of the asset, aggregating expert expectations for future capitalization while accounting for fundamental risks and earnings growth rates. By analyzing the consensus target price for Silence Therapeutics (SLN), an investor can assess the monetization potential of the RNA interference platform, where a high valuation reflects market confidence in the scalability of licensing fees and royalties from pharma behemoths.

Competing companies

Analyst Median Target tempus.com|Price Target Chart Qiagen QGEN|Ionis Pharmaceuticals, Inc. - Price Target Chart|RGEN - Price Target Chart|RNA (Avidity Corp) - Broker Consensus Forecast|CRSP: Analyst Consensus Forecast|Broker Consensus Forecast WGS|Price Target Chart Ultragenyx|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Analyst Consensus Forecast SRPT|Analyst Consensus Forecast Twist Bioscience Corp (TWST)|Price Target Chart 10x Genomics, Inc. TXG|Analyst Median Target intelliatx.com (NTLA)|Stoke Therapeutics, Inc. - Analyst Consensus Forecast|Analyst Median Target BioLife Solutions Inc BLFS|Wave Life Sciences Corp (WVE) - Price Target Chart|MAZE (Maze Therapeutics Corp) - Price Target Chart|SION (Sionna Therapeutics Inc) - Analyst Consensus Forecast|Average Forecast Price primemedicine.com PRME|Price Target Chart Taysha Gene Therapies, Inc. (TSHA)|uniQure NV - Broker Consensus Forecast|Analyst Consensus Forecast MGTX (MeiraGTx PLC)|RGNX - Consensus Target|Solid Biosciences Inc. - Analyst Consensus Forecast|Average Forecast Price ocugen.com|PACB (PacBio) - Consensus Target|Benitec Biopharma Inc - Fair Value Consensus|Consensus Target DSGN|RCKT (Rocket Corp) - Analyst Forecast Prices|Analyst Consensus Forecast FDMT|LXEO (lexeotx.com) - Fair Value Consensus|Analyst Consensus Forecast KRRO (Korro Bio)|Editas Medicine Inc (EDIT) - Average Forecast Price|PRQR - Price Target Chart|Fair Value Consensus CDXS (Codexis, Inc.)|SGMO: Analyst Consensus Forecast|Nautilus Bio (NAUT) - Analyst Consensus Forecast|Price Target Chart Metagenomi|Precision BioSciences Inc. - Forecast Levels Chart|Analyst Consensus Forecast GBIO|BOLD - Average Forecast Price|Exicure - Consensus Target|Analyst Consensus Forecast Imunon Inc IMNN|PHIO: Consensus Target|Mustang Bio, Inc. - Analyst Forecast Prices|RNAZ: Analyst Consensus Forecast|BNGO - Analyst Median Target|APDN (Applied DNA Sciences) - Analyst Consensus Forecast|Consensus Target bluebirdbio.com (BLUE)|Price Target Chart ImmunoPrecise Antibodies (IPA)|Analyst Median Target Omega Therapeutics Inc|Price Target Chart Singular Genomics Systems Inc OMIC|Analyst Median Target Regulus (RGLS)|SYRS - Price Target Chart|TBIO: Price Target Chart|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|Broker Consensus Forecast UBX